Clinicopathological and prognostic significance of FOXP3+ tumor infiltrating lymphocytes in patients with breast cancer: a meta-analysis by Daqing Jiang et al.
RESEARCH ARTICLE Open Access
Clinicopathological and prognostic significance
of FOXP3+ tumor infiltrating lymphocytes in
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Abstract
Background: The prognostic significance of FOXP3+ tumor-infiltrating lymphocytes (TILs) in patients with breast
cancer remains controversial. The aims of our meta-analysis are to evaluate its association with clinicopathological
characteristics and prognostic significance in patients with breast cancer.
Methods: PubMed, Embase, Cochrane Database and the Ovid Database were systematically searched (up to April
2015). The meta-analysis was performed using hazard ratio (HR), odds ratio (OR) and 95 % confidence intervals (CI) as
effect measures. Using the random-effects model, statistical analysis was performed using Stata software, version 12.0.
Results: Seventeen studies including 8277 patients with breast cancer were analyzed. The meta-analysis indicated that
the incidence difference of FOXP3+ TILs was significant when comparing the lymph node positive group to negative
group (OR = 1.305, 95 % CI [1.071, 1.590]), the histological grade III group to the I–II group (OR = 3.067, 95 % CI [2.288,
4.111]), the ER positive group to the negative group (OR = 0.435, 95 % CI [0.287, 0.660]), the PR positive group to the
negative group (OR = 0.493, 95 % CI [0.296, 0.822]), the HER2 positive group to the negative group (OR = 1.896, 95 % CI
[1.335, 2.692]), the TNBC group to the non TNBC group (OR = 2.456, 95 % CI [1.801, 3.348]). The detection of FOXP3+ TILs
was significantly correlated with the recurrence-free survival (RFS) of patients (HR = 1.752, 95 % CI [1.188–2.584]) and the
overall survival (OS) of patients (HR =1.447, 95 % CI [1.037–2.019]).
Conclusions: Our meta-analysis demonstrates that the presence of high levels of FOXP3+ TILs is associated with
prognosis for breast cancer patients and predicts lymph node metastasis, hormone receptor and HER-2 status.
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Background
Breast cancer is the most common type of diagnosed
cancer in women [1] and is still the second leading
cause of cancer-related death among women all over
the world [2]. So far, prediction of outcome is still not
optimal and additional predictive and prognostic factors
are needed to improve individualized treatment. A large
number of evidence has proved the existence of im-
mune surveillance function disorders against tumor
cells in breast cancer patients [3, 4]. Tumor may shape
the local immune microenvironment by recruiting lym-
phocytes, which regulate and release inflammatory me-
diators with pro-angiogenic or pro-metastatic effects
[5]. In the tumor microenvironment, complex network
of immune suppression influence the effects of antican-
cer treatments,and the accumulation of regulatory T cell
indicates an important working model of the network.
The investigations of tumor microenvironment can re-
veal the complex relationship between the tumor cell
biology and immune system. In order to control breast
cancer, a deep understanding of tumor microenviron-
ment will prove to be very important.
In the process of tumorigenesis, tumor progression
and metastatic spread, effective evasion of the immune
system by tumor cells is essential. The type, density and
location of tumor-infiltrating lymphocytes (TILs) within
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the tumor have shown to be predictors of survival rate in
breast cancer patients [6–8]. Regulatory T cells (Treg cells)
is considered to be involved in the maintenance of immune
tolerance, prevent autoimmune diseases and suppress anti-
tumor immune responses. More and more evidence indi-
cates that regulatory T cells play an important role in
immune evasion mechanisms of cancer [9–12]. Tumor
actively recruit and induce regulatory T cells to prevent
innate and adaptive immunity starts, effector function and
memory response, which may lead to a favorable environ-
ment for the development of cancer. Forkhead box protein
3 (FOXP3) is a member of the forkhead/winged-helix
family of transcription factors involved in regulating im-
mune system development and function [13, 14]. This
gene plays a important role in the generation of immuno-
suppressive CD4 +CD25+ regulatory T cells (Tregs), which
induce immune tolerance to antigens [14, 15]. Loss of
FOXP3 function leads to a lack of Tregs, resulting in lethal
autoaggressive lymphoproliferation, whereas FOXP3 over-
expression results in severe immunodeficiency [14, 15].
FOXP3 has been considered the most specific marker for
Treg cells [16, 17]. Tumor-induced FOXP3 + regulatory T
cells increasing indicates a potential barrier to attempts at
cancer immunotherapy. Cancer patients may benefit from
blocking the capacity of tumor cells to recruit Tregs. To
date, the prognostic significance of FOXP3+ TILs in breast
cancer remains controversial. However, a meta-analysis
demonstrating an association between FOXP3+ TILs de-
tection and prognosis has not yet been performed.
The aims of our study were to use meta-analysis to
demonstrate the correlation between FOXP3+ TILs and
the clinicopathological characteristics of breast cancer
and evaluate whether detection of FOXP3+ TILs can act
as a clinical predictor for patients with breast cancer.
Methods
Search strategy
PubMed, Embase, Cochrane Database and the Ovid Data-
base were systematically searched for studies addressing
the clinicopathological and prognostic correlation between
FOXP3+ TILs and breast cancer without language, place
of publication or time restrictions (up to April 2015). No
search restrictions were applied. Furthermore, the refer-
ence lists of the retrieved studies and reviews were
reviewed for further identification of potential relevant arti-
cles. The main search terms used were “FOXP3+”, “TILs”,
“Tumor-infiltrating lymphocytes”, “prognosis”, “Regulatory
T cell”, “breast cancer”, “breast carcinoma”.
Inclusion criteria
To ensure that our analysis is accurate and reliable, eli-
gible studies were selected based on the following criteria:
(i) The prognostic or clinicopathological significance of
FOXP3+ TILs detection in breast cancer patients with at
least one of the interested outcome measures was re-
ported in the study or can be calculated from published
data. (ii) Immunohistochemistry (IHC) detection methods
was used to detect specific FOXP3 antigens with mono-
clonal anti-human FOXP3. (iii) Samples were collected
from the core-needle biopsy or postoperative surgery
specimens. Reporting hazard ratio (HR), odds ratio (OR)
and their 95 % confidence interval (CI); if not, the re-
ported data of outcomes RFS, OS and pCR were sufficient
to calculate them.
Two reviewers (Z.H. Gao and D.Q. Jiang) independently
carried out literature searches and determined eligible arti-
cles based on the inclusion criteria. Disagreements between
reviewers were resolved via discussion and consensus. If
they can not reach agreement, a third researcher to deter-
mine the final results (J. He). If multiple publications were
based on the same patient population, we utilized the most
informative study.
Data extraction and quality assessment
We extracted our data based on Cochrane guidelines
[18]. Two reviewers (Z.H. Gao, D.Q. Jiang) reviewed eli-
gible studies independently, and any disagreements were
resolved through discussion and consensus. Extracted
information for this meta-analysis included: first author,
publication years, the journal, trial design, baseline pa-
tient characteristics, age range, dosing regimens, patient
eligibility, clinicopathological characteristics, follow-up
period, TILs site, cut-off point, end-points (RFS, OS,
pCR) , hazard ratio (HR) and 95 % confidence interval
(CI). The quality of the included studies was evaluated
according to the Newcastle-Ottawa scale (NOS) criteria
for cohort studies [19] Publication bias was assessed by
funnel plot. The written informed consents of all partici-
pants have been described and obtained by all the ori-
ginal studies that were included in our meta-analysis.
The original studies were conducted in accordance with
all local regulations, Good Clinical Practice principles
and the Declaration of Helsinki.
Statistical analysis
The prognostic effect of the meta-analysis were
recurrence-free survival (RFS), overall survival (OS). Ef-
fect measures regarding the effect in the meta-analysis
were reported as hazard ratio (HR) with 95 % confi-
dence interval (CI). The estimated odds ratio (OR) was
used to summarize the correlation between FOXP3+
TILs detection and breast cancer clinicopathological char-
acteristics. If the HR and its 95 % confidence interval (95 %
CI) were not reported directly in the original study, they
were calculated from the available data using software de-
signed by Tierney et al. [20] Heterogeneity among studies
was calculated using the Q test and I2 value indicates the
degree of heterogeneity [21]. I2 of <40 % indicates low
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heterogeneity [18]. If outcomes with low heterogeneity, a
fixed-effect model was used; otherwise random effects
models were used. The P value threshold for statistical
significance was set at 0.05 for effect sizes. The overall ana-
lysis was performed by assessing all the relevant researches
according to different clinicopathological parameters and
prognostic outcomes. Meanwhile, subgroup analysis was
completed in each clinicopathological parameter on the
basis of the different TILs site and different countries. A
sensitivity analysis was performed to evaluate the quality
and consistency of results. Publication bias was tested
using the funnel plot.
Statistical analysis was performed using Stata software,
version 12.0 (2011) (Stata Corp, College Station, TX, USA).
The recommendations of the Preferred Reporting Items
for Systematic Reviews and Meta-analyses (PRISMA) was
utilized as a guideline for this meta-analysis [22].
Ethics statement
The study was conducted in accordance with the local
regulations, and was approved by the Ethics Committee
of the Liaoning Province Cancer Hospital and Institute.
Results
Characteristics of the eligible studies
We identified a total of 125 studies in systematic lit-
erature search. 56 potentially relevant studies were
identified by reviewing the titles and abstracts. In the
remaining 56 studies, 39 studies were then excluded
because they do not meet the selection criteria. Fi-
nally, the remaining 17 studies met the selection cri-
teria and included in the meta-analysis [7, 23–38].
The searching and screening procedure is summarized
in Fig. 1. The 17 studies included 8277 eligible breast
cancer patients (sample size median: 153 [72–3277],
mean: 487). The studies were from Asia, Europe and
North America (Japan, Korea, China, France, United
Kingdom, Netherlands and Canada) and were published
between 2006 and 2014. All the included studies detected
FOXP3+ TILs with IHC method. In terms of the evalu-
ation of FOXP3+ TILs site, one study evaluated the sig-
nificance of FOXP3+ TILs detection at intratumoural,
peritumoral and distant stromal separately, [27] five stud-
ies evaluated the significance of FOXP3+ TILs at intratu-
moural and peritumoral separately, [7, 28, 33, 36, 37]
three evaluated the significance of FOXP3+ TILs detec-
tion only at intratumoural, [25, 34, 38] two studies
assessed the significance of FOXP3+ TILs detection only
at peritumoral [26, 30] and six studies evaluated the sig-
nificance of FOXP3+ TILs detection did not distinguish
sites (total sites) [23, 24, 29, 31, 32, 35]. Sixteen studies
provided HRs on RFS or OS to complete the meta-
analysis. Eight of the 16 studies were available for HRs on
OS, [7, 23, 27, 28, 30, 31, 33, 34] and eight studies were
available for HRs on RFS [7, 23, 25, 28–30, 32, 33, 35] The
main baseline characteristics is summarized in Table 1.
The quality of the included studies was assessed according
to the NOS and is summarized in Table 2.
Correlation of FOXP3+ TILs with clinicopathological
parameters
The incidence of FOXP3+ TILs in the lymph node metastasis
The meta-analysis of all involved studies on lymph node
metastasis showed a significantly higher incidence of
FOXP3+ TILs in the lymph node positive group relative
to the lymph node negative group (OR = 1.305, 95 % CI
[1.071, 1.590], I2 = 60.0 %). Then subgroup analysis were
performed on TILs site (Intratumoural: OR = 1.121, 95 %
CI [0.953, 1.318], I2 = 38.4 %; Peritumoral: OR = 2.917,
95 % CI [1.067, 7.971], I2 = .%; Total: OR = 1.590, 95 % CI
Fig. 1 Flow chart of studies selection
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2011 France 162 YES/YES NR FOXP3+/CD8+ B-NC/post Peritumoral IHC YES RFS; OS NR
Lee S et al.
[30]
2013 Korea 86 NR/YES NR FOXP3+ NR Peritumoral IHC NR RFS;OS 73.5(24.2–120.0)
Mahmoud
SMA et al. [27]
2011 United
Kingdom
1445 NR/YES NR FOXP3+ Post Intratumoural;distant
stromal; peritumoral
IHC/TMA YES OS;RFS 128(4–243)
Liu F et al. [7] 2011 China 1270 NO/YES 52(19–92) FOXP3+/CD8+ Post Intratumoural;
peritumoral
IHC YES OS; RFS 66(1–78)
West NR et al.
[32]
2013 Canada 175 NR NR FOXP3+/CD8+ Post Total IHC YES RFS; OS 83




299 NR/YES NR FOXP3+ Post Total IHC YES RFS; OS 87.6(2.4–135.6)
Takenaka M
et al. [31]
2013 Japan 100 NO/NR NR FOXP3+ Post Total IHC YES OS; RFS NR
Maeda N et al.
[35]
2014 Japan 90 NO/YES NR FOXP3+ Post Total IHC YES OS; RFS 67(7.8–90.5)
Sun S et al.
[36]




IHC YES OS; RFS 72(8.04–102.24)
Aruga T et al.
[24]
2009 Japan 87 YES/NR 51(23–69) FOXP3+ B-NC Total IHC NR OS; RFS 46.3(5.3–89.1)
De Kruijf EM
et al. [25]
2010 Netherlands 556 NO/YES 57(23–96) HCA2/HC10/
Foxp3+
Post Intratumoural IHC YES OS; RFS 228(0–276)
Liu F et al.
[28]
2012 China 132 YES/YES 53(38–72) FOXP3+ B-NC/post Intratumoural;
peritumoral
IHC YES pCR; OS; RFS 62(18–73)
Liu S et al.
[34]
2014 Canada 3277 NR/YES 58.9(23–95) FOXP3+/CD8+ Post Intratumoural IHC/TMA NR OS; RFS 151(1.2–222)
Kim ST et al.
[29]
2013 Korea 72 YES/NR 49(16–83) FOXP3+/CD8
+/CD4+
B-NC/post Total IHC YES RFS 34(21.9–38.3)
Tsang JY et al.
[37]




IHC/TMA YES NO NR
Kim S et al.
[33]




IHC YES OS; RFS 69
Seo AN et al.
[38]
2013 Korea 153 YES/NR NR FOXP3+/CD8
+/CD4+
B-NC/post Intratumoural IHC YES pCR; NR
CRT, chemoradiotherapy (pre/postoperation); TILs Tumor-infiltrating lymphocytes; IHC Immunohistochemistry; TMA tissue microarrays; B-NC before Neoadjuvant chemotherapy; post postoperative; NR Not reported; RFS











[1.057, 2.394], I2 = 65.9 %) and different countries (Asia:
OR = 1.636, 95 % CI [0.993, 2.693], I2 = 71.2 %; Europe
and North America: OR = 1.209, 95 % CI [1.017, 1.437],
I2 = 41.6 %). The results of pooled analysis on breast
cancer lymph node metastasis are summarized in
Table 3.
Tumour size
The incidence of FOXP3+ TILs in the tumour size >2 cm
group was higher than tumour size ≤2 cm group, but the
difference did not reach statistical significance (OR = 1.151,
95 % CI [0.997, 1.329], I2 = 25.0 %). Then subgroup analysis
were performed on TILs site (Intratumoural: OR = 1.098,
95 % CI [0.966, 1.247], I2 = 0.0 %; Total: OR = 1.268, 95 %
CI [0.954, 1.686], I2 = 37.0 %) and different countries (Asia:
OR = 1.296, 95 % CI [0.867, 1.935], I2 = 54.9 %; Europe
and North America: OR = 1.146, 95 % CI [1.016, 1.293],
I2 = 0.0 %). The differences were statistically significant
in the European and American group.
Histological grade
The detection of FOXP3+ TILs in histopathologic
specimen may indicate the degree of histological grade
(III versus I, overall: OR = 3.769, 95 % CI [2.596, 5.472],
I2 = 64.6 %; III versus II, OR = 2.299, 95 % CI
[1.719,3.075], I2 = 80.3 %; II versus I, OR = 1.596, 95 %
CI [1.172,2.174], I2 = 51.3 %). Then, subgroup analyses
were completed on TILs site (Intratumoural: III versus I,
OR = 3.360, 95 % CI [1.774, 6.363], I2 = 79.0 %; III versus II,
OR = 1.945, 95 % CI [1.551,2.439], I2 = 56.9 %; II versus I,
OR = 1.790, 95 % CI [1.191,2.691], I2 = 51.2 %. Total: III
versus I, OR = 4.298, 95 % CI [3.221, 5.736], I2 = 0.0 %; III
versus II, OR = 3.422, 95 % CI [2.706,4.326], I2 = 0.0 %; II
versus I, OR = 1.260, 95 % CI [0.947,1.677], I2 = 18.7 %.)
and different countries (Asia: III versus I, OR = 6.248, 95 %
CI [3.627, 10.763]; III versus II, OR = 2.287, 95 % CI
[1.740,3.005]; II versus I, OR = 2.732, 95 % CI [1.636,4.562].
Europe and North America: III versus I, OR = 3.342, 95 %
CI [2.270, 4.920], I2 = 60.0 %; III versus II, OR = 2.304, 95 %
CI [1.561,3.400], I2 = 85.2 %; II versus I, OR = 1.351, 95 %
CI [1.087, 1.680], I2 = 0.0 %).
ER, PR and HER2 status
The incidence of FOXP3+ TILs was significantly different
between the ER positive and ER negative groups (overall:
OR = 0.435, 95 % CI [0.287, 0.660], I2 = 90.3 %; Intratu-
moural: OR = 0.571 95 % CI [0.276, 1.181], I2 = 95.7 %;
Total: OR = 0.347, 95 % CI [0.252, 0.478], I2 = 31.7 %; Asia:
OR = 0.419, 95 % CI [0.193, 0.908], I2 = 88.8 %; Europe
and North America: OR = 0.481, 95 % CI [0.324, 0.714],
I2 = 84.8 %), as well as PR positive and negative
groups (overall: OR = 0.493, 95 % CI [0.296, 0.822],
I2 = 89.9 %; Intratumoural: OR = 0.417 95 % CI [0.128,
1.357], I2 = 96.8 %; Total: OR = 0.501, 95 % CI [0.405,
Table 2 The assessment of the risk of bias in each cohort study using the Newcastle–Ottawa scale
Study Selection (0–4) Comparability (0–2) Outcome (0–3) Total
REC SNEC AE DO SC AF AO FU AFU
Ladoire S et al. [26] 1 1 1 1 0 0 1 0 0 5
Lee S et al. [30] 0 1 1 0 0 0 1 1 0 4
Mahmoud SMA et al. [27] 1 1 1 1 0 0 1 1 0 6
Liu F et al. [7] 1 1 1 1 1 0 1 1 0 7
West NR et al. [32] 1 1 1 1 0 0 1 1 0 6
Bates GJ et al. [23] 1 1 1 1 0 0 1 1 0 6
Takenaka M et al. [31] 1 1 1 1 0 0 1 1 0 6
Maeda N et al. [35] 1 1 1 1 0 0 1 1 0 6
Sun S et al. [36] 1 1 1 1 1 0 1 1 1 8
Aruga T et al. [24] 1 1 1 1 0 0 0 1 0 5
De Kruijf EM et al. [25] 1 1 1 1 1 0 1 1 0 7
Liu F et al. [28] 1 1 1 1 0 0 1 1 0 6
Liu S et al. [34] 1 1 1 1 0 0 1 1 0 6
Kim ST et al. [29] 0 1 1 1 0 0 0 0 0 3
Tsang JY et al. [37] 1 1 1 1 0 0 0 0 0 4
Kim S et al. [33] 1 1 1 1 0 0 0 1 0 5
Seo AN et al. [38] 1 1 1 1 0 0 0 0 0 4
REC representativeness of the exposed cohort; SNEC selection of the non exposed cohort; AE ascertainment of exposure; DO demonstration that outcome of
interest was not present at start of study; SC study controls for age, sex; AF study controls for any additional factor; AO assessment of outcome; FU follow-up long
enough for outcomes to occur (36 Months); AFU Adequacy of follow up of cohorts (≥90 %).“1” means that the study is meeted the item and “0” means the
opposite situation
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Table 3 The detailed subgroup analysis results of clinicopathological parameters
Clinicopathological parameters TILs site Different countries
Any Intratumoural Peritumoral Total Asia Europe/North
America
Age > 50 vs. ≤ 50 (OR) 0.867[0.699,1.076];
I2 = 66.3 %; z = 1.30;
p = 0.195
0.855[0.562,1.303];
I2 = 89.8 %; z = 0.73;
p = 0.466
_ 0.804[0.669,0.965 ];
I2 = 0.0 %; z = 2.35;
p = 0.019
1.081[0.894,1.307 ];
I2 = 0.0 % ; z = 0.81 ;
p = 0.420
0.731[0.592, 0.901];
I2 = 55.6 %; z = 2.93 ;
p = 0.003
Tumour size > 2 cm vs. ≤ 2 cm
(OR)
1.151[0.997,1.329];
I2 = 25.0 %; z = 1.92 ;
p = 0.055
1.098[0.966,1.247];
I2 = 0.0 %; z = 1.43;
p = 0.151
_ 1.268[0.954,1.686 ];
I2 = 37.0 %; z = 1.64 ;
p = 0.101
1.296[0.867,1.935 ];
I2 = 54.9 %; z = 1.26 ;
p = 0.206
1.146[1.016 , 1.293];
I2 = 0.0 %; z = 2.22;
p =0.026
LN(+) vs. LN(−)(OR) 1.305[1.071 ,1.590];
I2 = 60.0 %; z = 2.64;
p =0.008
1.121[0.953 ,1.318];
I2 = 38.4 %; z = 1.37;
p = 0.169
2.917[1.067 ,7.971];
I2 = .%; z = 2.09;
p = 0.037
1.590[1.057 ,2.394];
I2 = 65.9 %; z = 2.22;
p = 0.026
1.636[0.993 ,2.693];
I2 = 71.2 % ; z = 1.93;
p =0.053
1.209[1.017 ,1.437 ];
I2 = 41.6 %; z = 2.16;
p =0.031
pT:T3/T4 vs.T1/T2 (OR) 0.990[0.748 ,1.310];
I2 = 0.0 % ; z = 0.07;
p =0.943
0.990[0.748 ,1.310];
I2 = 0.0 % ; z = 0.07;
p = 0.943
_ _ _ 0.990[0.748 ,1.310];
I2 = 0.0 % ; z = 0.07;
p = 0.943
StageIII/IV vs.I/II (OR) 1.115[0.631 ,1.970 ];
I2 = 68.7 %; z = 0.37;
p =0.709
0.925[0.642 ,1.335];
I2 = 30.7 %; z = 0.41;
p = 0.679
_ _ 1.181[0.418,3.341 ];
I2 = 79.1 %; z = 0.31;
p =0.754
_
Histological grade:III vs.I(OR) 3.769[2.596, 5.472];
I2 = 64.6 %; z = 6.98;
p < 0.0001
3.360[1.774, 6.363];
I2 = 79.0 %; z = 3.72;
p < 0.0001
_ 4.298[3.221, 5.736];
I2 = 0.0 %; z = 9.88;
p < 0.0001
6.248[3.627,10.763];
I2 = .%; z = 6.60;
p < 0.0001
3.342[2.270, 4.920];
I2 = 60.0 % ; z = 6.11;
p < 0.0001
III vs. II (OR) 2.299[1.719,3.075];
I2 = 80.3 %; z = 5.61;
p < 0.0001
1.945[1.551,2.439]; I2 = 56.9 %; z = 5.76;
p < 0.0001
_ 3.422[2.706,4.326];
I2 = 0.0 %; z = 10.29;
p < 0.0001
2.287[1.740,3.005]; I2 = .%; z = 5.94;
p < 0.0001
2.304[1.561, 3.400];
I2 = 85.2 % ; z = 4.20;
p < 0.0001
II vs. I (OR) 1.596[1.172,2.174];
I2 = 51.3 %; z = 2.97;
p = 0.003
1.790[1.191,2.691];
I2 = 51.2 %; z = 2.80;
p = 0.005
_ 1.260[0.947,1.677];
I2 = 18.7 %; z = 1.37;
p = 0.171
2.732[1.636,4.562];
I2 = .%; z = 3.84;
p < 0.0001
1.351 [1.087, 1.680];
I2 = 0.0 % ; z = 2.64 ;
p = 0.008
Lymphatic invasion (+) vs.(−) (OR) 1.382[0.844,2.262];
I2 = 42.8 %; z = 1.29;
p = 0.198
_ _ _ 2.071[1.045,4.102];
I2 = 0.0 %; z = 2.09;
p = 0.037
_
Vessel invasion (+) vs.(−) (OR) 1.107[0.750,1.634];
I2 = 24.0 %; z = 0.51;
p = 0.608
_ _ 1.107[0.750,1.634];
I2 = 24.0 %; z = 0.51;
p = 0.608
_ _
ER (+) vs.(−) (OR) 0.435[0.287,0.660];
I2 = 90.3 %; z = 3.91;
p < 0.0001
0.571[0.276,1.181];
I2 = 95.7 %; z = 1.51;
p = 0.131
_ 0.347[0.252,0.478];
I2 = 31.7 %; z = 6.48;
p < 0.0001
0.419[0.193,0.908];
I2 = 88.8 %; z = 2.21;
p = 0.027
0.481[0.324,0.714];
I2 = 84.8 %; z = 3.63;
p < 0.0001
PR (+) vs.(−) (OR) 0.493[0.296,0.822];
I2 = 89.9 %; z = 2.71;
p = 0.007
0.417[0.128,1.357];
I2 = 96.8 %; z = 1.45;
p = 0.146
_ 0.501[0.405,0.621];
I2 = 0.0 %; z = 6.31;
p < 0.0001
0.432[0.195,0.959];
I2 = 85.1 %; z = 2.06;
p = 0.039
0.594[0.373,0.945];
I2 = 79.2 %; z = 2.20;
p = 0.028
HER2 (+) vs.(−) (OR) 1.896[1.335,2.692];
I2 = 75.1 %; z = 3.58;
p < 0.0001
1.141[0.718,1.814];
I2 = 81.6 %; z = 0.56;
p = 0.576
2.299[1.066,4.960];
I2 = .%; z = 2.12; p =
0.034
3.651[2.638,5.052];
I2 = 0.0 %; z = 7.81;
p < 0.0001
1.684[0.881,3.218];
I2 = 74.4 %; z = 1.58;
p = 0.115
2.059[1.203,3.523]; I2












Table 3 The detailed subgroup analysis results of clinicopathological parameters (Continued)
Molecular Subtypes
:TNBC vs. nTNBC (OR)
2.456[1.801,3.348];
I2 = 11.3 %; z = 5.68;
p < 0.0001
3.514[1.563,7.901];
I2 = .%; z = 3.04;
p = 0.002
_ 2.342[1.625,3.375];
I2 = 17.5 %; z = 4.57;
p < 0.0001
2.990[1.666,5.366];
I2 = 24.6 %; z = 3.67;
p < 0.0001
2.230[1.642,3.029];
I2 = .%; z = 5.14;
p < 0.0001
Luminal A vs. Luminal B vs.
Luminal HER2 vs. HER2-enriched
vs. Basal-like
_ p < 0.0001 _ p < 0.0001 p < 0.0001 _











0.621], I2 = 0.0 %; Asia: OR = 0.432, 95 % CI [0.195,
0.959], I2 = 85.1 %; Europe and North America: OR =
0.594, 95 % CI [0.373, 0.945], I2 = 79.2 %). Moreover, there
was a significant difference in the incidence of FOXP3+
TILs detection between the HER2 positive group and
HER2 negative group (overall: OR = 1.896, 95 % CI [1.335,
2.692], I2 = 75.1 %; Intratumoural: OR = 1.141 95 % CI
[0.718, 1.814], I2 = 81.6 %; Total: OR = 3.651, 95 % CI
[2.638, 5.052], I2 = 0.0 %; Asia: OR = 1.684, 95 % CI [0.881,
3.218], I2 = 74.4 %; Europe and North America: OR =
2.059, 95 % CI [1.203, 3.523], I2 = 81.0 %).
Molecular subtypes
Those studies which included five molecular subtypes: lu-
minal A, luminal B, luminal-HER2, HER2 enriched and
basal-like showed that the status of FOXP3+ TILs infiltra-
tion was increased corresponding to the order of the mo-
lecular subtypes from well to poor. The meta-analysis of all
involved studies on the five molecular subtypes showed a
significant difference in the status of FOXP3+ TILs infiltra-
tion among the five molecular subtypes (p < 0.0001). The
incidence of TNBC was more likely to increase in high
FOXP3+ TILs group than in low FOXP3+ TILs group
(overall: OR = 2.456, 95 % CI [1.801, 3.348], I2 = 11.3 %;
Intratumoural: OR = 3.514 95 % CI [1.563, 7.901], I2 = .%;
Total: OR = 2.342, 95 % CI [1.625, 3.375], I2 = 17.5 %; Asia:
OR = 2.990, 95 % CI [1.666, 5.366], I2 = 24.6 %; Europe and
North America: OR = 2.230, 95 % CI [1.642,3.029]).
Impact of FOXP3+ TILs on survival outcomes (RFS and OS)
To evaluate the prognostic effect for detection of FOXP3+
TILs in breast cancer patients more deeply, a meta-
analysis was performed on HR for RFS or OS. HRs for
RFS were available in eight studies. The evaluated pooled
HRs indicated that high FOXP3+ TILs group was associ-
ated with a significantly decreased RFS (HR = 1.752, 95 %
CI [1.188–2.584], p = 0.005). As shown in the subgroup
analysis based on TILs site, a poor prognosis for RFS in
patients with breast cancer was shown by the detection of
FOXP3+ TILs in Intratumoural and Peritumoral, but not
in Total (Intratumoural: HR = 1.983, 95 % CI [1.232,
3.190], I2 = 44.7 %; Peritumoral: HR = 2.206, 95 % CI
[1.287, 3.781], I = 0.0 %; Total: HR = 1.312, 95 % CI [0.580,
2.969], I2 = 79.8 %). Sensitivity analysis was completed
without the low quality studies (NOS score < 5) and the
results were the same (overall: HR = 1.741, 95%CI 1.114-
2.720; P = 0.015). But in TNBC patients, evaluated pooled
HRs indicated that high FOXP3+ TILs group was associ-
ated with a significantly increased RFS (HR =0.503, 95 %
CI [0.324–0.779], p = 0.002).
Furthermore, eight studies provided HRs on OS and
the pooled results showed that breast cancer patients in
the high FOXP3+ TILs group were significantly associ-
ated with a poor OS (HR =1.447, 95 % CI [1.037–2.019],
p = 0.030). The pooled results of the subgroup analysis
were similar to the results of the overall analysis in the
Asia group patients (Asia: HR = 2.413, 95 % CI [1.363,
4.270], I2 = 24.4 %), but not in the Europe and North
America group patients (Europe and North America:
HR = 1.064, 95 % CI [0.827, 1.368], I2 = 69.4 %). On the
contrary, the pooled results showed that TNBC patients
in the high FOXP3+ TILs group were significantly asso-
ciated with a favourable OS (HR =0.509, 95 % CI
[0.356–0.728], p < 0.001). The evaluated pooled HRs for
PFS and OS are summarized in Fig. 2. Egger’s test was
used to detect publication bias. There were no signifi-
cant publication bias was found (Fig. 3).
Discussion
Although the application of standardized comprehensive
treatment has been significantly improved the prognosis
of breast cancer patients, but the tumor recurrence and
metastasis is still a serious challenge for doctors and pa-
tients. Breast cancer is a very heterogeneous disease,
which can be categorized into four main molecular sub-
classes based on hormone receptor and HER-2 expres-
sion. Although these subclasses have different clinical
and biological characteristics, as strong heterogeneity
within subgroups, such biology-based classification is
still unsatisfactory. Interaction between malignant tissue
and the immune system play a critical role in the process
of tumor growth and metastasis. FOXP3 has been con-
sidered the most specific marker for Treg cells [16, 17].
More and more evidence indicates that regulatory T cells
play an important role in immune evasion mechanisms
of cancer [9–12]. However, the clinicopathological and
prognostic significance of FOXP3+ TILs detection in pa-
tients with breast cancer remains controversial. This
meta-analysis provided evidence to estimate the signifi-
cance of FOXP3+ TILs detection in patients with breast
cancer by summarizing all related studies.
Our present meta-analysis demonstrated that the de-
tection of FOXP3+ TILs was feasible on core-needle bi-
opsy and excisional specimen and could act as a risk
factor for lymph node metastasis in patients with breast
cancer. Our pooled results indicated that high levels of
FOXP3+ TILs were significantly associated with high histo-
logical grade. Furthermore, our pooled analysis showed
that the presence of high levels of FOXP3+ TILs was asso-
ciated with ER negative, PR negativity, HER2 Positive and
TNBC. This conclusion was further supported by the
meta-analysis results on RFS and OS. Approximately two
thirds of the patients diagnosed with invasive breast cancer
have positive hormone receptors [39]. Most of the included
studies reported that FOXP3+ TILs was an indicator of
poor prognosis applied unstratified breast cancer. There-
fore, our pooled results might largely reflect the majority
ER Positive population. Subsequently, sensitivity analysis
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Fig. 2 Evaluated hazard ratios (HR) summary for RFS (a) and OS (b). a HR for recurrence-free survival (RFS) with FOXP3+ TILs detection. b HR for
overall survival (OS) with FOXP3+ TILs detection
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confirmed the results were still significant. No publication
bias was confirmed with a funnel plot. There were several
possible explanations for the correlation between FOXP3+
TILs and lymph node metastasis and poor survival. One
possible explanation may be that FOXP3+ TILs reflect
tumor-induced immune evasion in breast cancers. In
addition, high levels of FOXP3+ TILs was associated with
poor survival factors, such as high histological grade, hor-
mone receptor negative and HER2 Positive.
But in TNBC patients, evaluated pooled HRs indicated
that high FOXP3+ TILs group was associated with a sig-
nificantly improved RFS and OS. So far, very few studies
have been powered to evaluate if FOXP3+ TILs influence
clinical outcomes in different breast cancer molecular sub-
types. Therefore, this subgroup analyses still have limited
power. There were several possible explanations for this
result. The main explanation may be that the favorable
prognostic effect of FOXP3+ TILs in TNBC breast cancer
may be primarily due to CD8+ T-cell infiltration. In
addition, Tregs require close contact with target cells to
exert suppression [40]. Currently, one research indicates
that fewer than 20 % of CD4 + FOXP3+ lymphocytes were
in direct contact with CD8+ TIL in the triple negative co-
hort [32]. Therefore, Tregs in TNBC may not exert signifi-
cant suppression on CTLs. Moreover, multiple important
factors of anti-tumour immunity can be active in TNBC
despite the presence of Tregs. The prognostic correlations
of FOXP3+ TILs could be affected by tumor microenvir-
onment, including tumor location, histological and mo-
lecular subtypes, as well as different types of immune
Fig. 3 Funnel plot for potential publication bias. a Funnel plot analysis of studies on RFS b Funnel plot analysis of studies on OS. The funnel plot indicates
that there was no significant publication bias
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response. Further studies to explore the functional status
and action modes of different subsets of TILs in different
breast cancer molecular subtypes will lead us to further
understand the mechanisms and provide additional clues
for immunotherapy.
This meta-analysis has several limitations. First, the lim-
ited number of stratified breast cancer studies would have
influenced the statistical power of our results. Second, het-
erogeneity could not be eliminated, its existence forced us
to use a relatively conservative random effect model. Third,
our research is based on statistical data, rather than indi-
vidual patient data, which may not be able to provide a ro-
bust estimate of association. Despite the limitations of our
study, our meta-analysis is the first study to demonstrate
the correlation between FOXP3+ TILs and the clinicopath-
ological characteristics and prognosis in breast cancer.
Conclusions
In conclusion, our meta-analysis demonstrates that the
presence of high levels of FOXP3+ TILs is associated with
prognosis for breast cancer patients and predicts lymph
node metastasis, hormone receptor and HER-2 status. In
the future, high-quality, well designed and large-scale mul-
ticenter studies are needed to explore the functional role
of different TILs subsets in different breast cancer mo-
lecular subtypes. In addition, it can provide the basis for
the immunotherapy of different molecular subtypes of
breast cancer.
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